stockrowNeurocrine Biosciences, Inc.
NBIX Healthcare Drug Manufacturers Specialty & Generic
Neurocrine Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 21.4% from fiscal 2024.
- Revenue
- +41.2%
- EPS
- −3.67%
- Free cash flow
- +79.0%
Quarter to September 2026, against a year earlier
Follow NBIX
Alert me
Neurocrine Biosciences, Inc. (NBIX) P/S ratio
As of 5 November 2026, Neurocrine Biosciences, Inc. (NBIX) trades at a P/S ratio of 4.4×. Over the past ten years it has ranged from 0.0× (March 2015) to 225× (November 2015); the current reading is higher than 5% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 2.1× and above the Healthcare sector median of 3.5×.
P/S ratio, daily
Embed this chart
Annual newest first
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 4.9× | (15.21%) |
| FY2024 | 5.8× | (14.68%) |
| FY2023 | 6.8× | (11.74%) |
| FY2022 | 7.7× | 8.71% |
| FY2021 | 7.1× | (16.69%) |
| FY2020 | 8.5× | (31.71%) |
| FY2019 | 12.5× | (12.48%) |
| FY2018 | 14.3× | (63.90%) |
| FY2017 | 39.5× | (57.26%) |
| FY2016 | 92.5× | (57.49%) |
Quarterly newest first
| Period | P/S ratio | Change |
|---|---|---|
| Sep 2026 | 3.9× | (22.84%) |
| Jun 2026 | 5.0× | 18.23% |
| Mar 2026 | 4.3× | (13.50%) |
| Dec 2025 | 4.9× | (5.15%) |
| 36 more quarters | Free account |
Against its own ten years
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| VTRS Viatris Inc. compare | 1.5× |
| HLN Haleon PLC Sponsored ADR compare | 2.3× |
| ELAN Elanco Animal Health Incorporated compare | 2.4× |
| ZTS Zoetis Inc. compare | 3.6× |
| RDY Dr. Reddy's Laboratories Ltd compare | 3.6× |
| ALKS Alkermes plc compare | 4.3× |
| NBIX Neurocrine Biosciences, Inc. | 4.4× |
| KNSA Kiniksa Pharmaceuticals International, plc compare | 7.3× |
| UTHR United Therapeutics Corporation compare | 7.6× |
| Drug Manufacturers Specialty & Generic industry median | 2.1× |
| Healthcare sector median | 3.5× |
| Market median | 1.9× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on NBIX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement